Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01476137 · ClinicalTrials.gov registry record · Phase 1
A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers
A Phase 1 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 1
- Development phase
- 335
- Enrollment target
NCT01476137: Completed Phase 1 study, sponsored by GlaxoSmithKline.
NCT01476137 is a Phase 1 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 335 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (458% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01476137, a Phase 1 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 335 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether the MEK inhibitor and the AKT inhibitor can be given in combination and if the combination is effective treatment for patients with solid tumors, including breast cancer and endometrial cancer, and for patients with multiple myeloma.
Primary Outcome
Adverse events, serious adverse events, dose reductions or delays, withdrawals due to toxicities and changes in laboratory values and vital signs
Interventions
- DRUG GSK1120212
- DRUG GSK2110183
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 335 participants |
| Start Date | 2011-10-26 |
| Est. Completion | 2013-03-12 |
| Phase | Phase 1 |
What the finished NCT01476137 record still lists
NCT01476137 is an interventional study that assigns participants to a tested intervention. The registered 335 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (458% higher).
The record links to 0 conditions, and to 2 interventions - of which GSK1120212 is the first listed.
NCT01476137 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01476137 about?
NCT01476137 is a clinical study titled "A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers". The purpose of this study is to determine whether the MEK inhibitor and the AKT inhibitor can be given in combination and if the combination is effective treatment for patients with solid tumors, including breast cancer and endometrial cancer, and for patients with multiple myeloma.
What is the current status of trial NCT01476137?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 335 participants. The study started on 2011-10-26. Estimated completion is 2013-03-12.
What interventions are being tested in trial NCT01476137?
The interventions under investigation include: GSK1120212 (DRUG), GSK2110183 (DRUG).
Who is sponsoring clinical trial NCT01476137?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01476137's enrollment target sits among peer trials
335 108th of 2000 higher than 1,893 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04134754 · 335 participants · NA
Carbon Dioxide (CO2) Chemosensitivity and SUDEP
- NCT05554406 · 335 participants · Phase 2
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- NCT06183437 · 335 participants · Phase 4
The STOP-MED CTRCD Trial
- NCT06885177 · 335 participants · NA
TECTONIC CAD IVL IDE Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI